|
Original-Research: INDUS Holding AG - from NuWays AG
Classification of NuWays AG to INDUS Holding AG
RT feedback: Strong FCF and well filled M&A pipeline Topic: On Monday we hosted a digital roundtable with INDUS, here are our key takeaways. M&A pipeline well filled: INDUS expects to see another deal to sign within the Infrastructure segment this year. However, the purchase price is likely not to be paid until FY25e. Further, INDUS has in prospect to spend around € 50-70m on M&A next year. Considering the recent decline in acquisition multiples for German SME’s, it is now a good time for INDUS to expand its portfolio in our view. Infrastructure shows a solid development in FY24 (10.2% EBIT margin in 9M, +1.9ppts yoy), which is expected to continue for FY25e. In addition, the Engineering segment should improve at least slightly next year. As communicated by management in the Q2 CC, product mix in H2’24e is much more favorable than in H1. Consequently, the operating margin in Q3 already improved considerably compared to H1’24 (9.0% vs. 5.2% in H1). In our view H2’24e should be a better reference point for FY25e than the muted H1. On the other hand, Materials should be more challenging next year. While the medical companies show resilience, companies in the metal production and processing sectors are more affected by the current difficult macro environment. In addition, order backlog in Materials decreased over the last year, which puts further pressure on the top-line (€ 120m backlog in 9M’24 vs. € 153m end of FY23). Strong Free Cashflows: INDUS continues to expect above € 110m in FCF this year (eNuW: € 115m), delivering a strong FCFY’24e of c. 10% (eNuW). Beyond that, a further reduction in working capital for FY25e looks plausible, which is however dependent on the sales development next year. This should support free cashflows in FY25e. Already in 9M, working capital decreased c. € 33m yoy to € 506m (vs. € 538m end of 9M’23; € 618m end of 9M’22), thanks to an ease of supply chains, muted sales growth and an active working capital management. We continue to like the stock and confirm INDUS as one of NuWays’ Alpha Picks. Reiterate BUY with an unchanged PT of € 34, based in FCFY’24e. You can download the research here: http://www.more-ir.de/d/31361.pdf For additional information visit our website: www.nuways-ag.com/research Contact for questions: NuWays AG - Equity Research Web: www.nuways-ag.com Email: research@nuways-ag.com LinkedIn: https://www.linkedin.com/company/nuwaysag Adresse: Mittelweg 16-17, 20148 Hamburg, Germany ++++++++++ Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte. Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse. ++++++++++
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
||||||||||||||||||||
2032767 19.11.2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
